Current antiviral strategies against HIV rely on structure–function analysis of HIV reverse transcriptase (RT) and protease (PR). The third viral pol gene product, HIV integrase (IN), is also a good target for drug discovery, since IN is essential for retroviral replication and, moreover, it has no obvious functional analogue in the host. IN forms a ternary complex with metal ions and DNA and has a mechanism of catalysis common with other polynucleotidyl transferases. Although there is no structural information for full‐length IN available, structures of all three functional IN domains have been determined by X‐ray crystallography and NMR spectroscopy. The N‐terminal domain has a novel zinc‐binding fold, the catalytic domain shares a common structural motif with other polynucleotidyl transferases, and the C‐terminal DNA‐binding domain has a Src‐homology‐3‐like fold. This structural information provides the basis for drug development. In turn, increasing numbers of IN inhibitors identified so far may serve structure–function analysis of IN. The final goal is the development of new classes of anti‐HIV drugs, which can be added to the repertoire of anti‐RT and anti‐PR drugs.